Thioredoxin Systems AB is pioneering the development of EbsArgent™, an innovative antibiotic regimen specifically designed to combat complicated urinary tract infections (cUTIs) caused by antibiotic-resistant bacteria. This technology employs a novel mechanism of action that targets bacterial antioxidant redox systems, particularly focusing on the thioredoxin reductase enzyme. By utilizing a combination of ebselen and silver ions, EbsArgent™ exhibits strong synergistic bactericidal activity against a wide range of pathogens, including those classified as critical priority by the World Health Organization (WHO). Notably, EbsArgent™ has shown effectiveness against multidrug-resistant strains and has demonstrated an ability to prevent biofilm formation, a significant factor in the persistence of cUTIs.

The unique approach of EbsArgent™ not only addresses the urgent challenge of antimicrobial resistance (AMR) but also maintains low toxicity to mammalian cells, making it a promising candidate for clinical use. The mechanism of action involves the irreversible inhibition of bacterial thioredoxin reductase by ebselen, which is distinct from the human enzyme, thereby minimizing potential side effects. Thioredoxin Systems AB continues to build on the legacy of its founder, Professor Arne Holmgren, whose groundbreaking research laid the foundation for this innovative antibiotic technology. With several patents protecting their discoveries, the company is committed to advancing EbsArgent™ through preclinical development, aiming to provide an effective solution for the growing threat of antibiotic-resistant infections.

Sweden

Thioredoxin Systems AB is a biotechnology company developing a novel antibiotic regimen against pathogenic bacteria. EbsArgent is a patented combination of ebselen and silver, capable of functioning as an antiseptic, antibacterial in food production, and as a medicinal product. With its versatility and ability to act on a wide range of multi-drug resistant bacteria, it is among the most promising antibiotic regimen under development today.

Thioredoxin Systems AB

Company Details